Nivolumab + ipilimumab: Added benefit in pleural mesothelioma with non-epithelioid tumour histology
The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line ...
Oct 4, 2021
0
0